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The purpose of this study was to evaluate the efficacy of low-dose chemotherapy in infants with localised and unresectable
neuroblastoma (NB). All consecutive infants with localised NB and no N-myc amplification were eligible in the SFOP-NBL 94 study.
Primary tumour was deemed as unresectable according to imaging data showing any risk of immediate resection. Diagnostic
procedures and staging were conducted according to INSS recommendations. For children, provided that they had no threatening
symptom (i.e. vital risk or dumb-bell NB with neurologic deficit), chemotherapy consisted in low-dose cyclophosphamide
(5mg
 1kgday
 1 5 days) and vincristine (0.05mgkg
 1 at day 1)–CV and repeated one to three times every 2 weeks until surgical
excision can be safely performed. No postoperative treatment was given. Between January 1995 and December 1999, 134
consecutive infants with localised NB were registered in the study, of whom 39 had an unresectable NB without N-myc amplification.
Among them 28 had no threatening symptom and received CV according to the protocol. Objective response was observed in 14
(50%) and the other 14 were given second-line chemotherapy because of no response. Surgery was attempted in 38 patients
including 14 after CV alone, leading to complete resection in 23. Relapses occurred in four patients all local. Survival and event-free
survival were 100 and 9075% with a median follow-up of 55 months (range 33–93). In conclusion primary low-dose chemotherapy
without anthracyclines is efficient in about half of the infants presenting with an unresectable NB and no N-myc amplification, allowing
excellent survival rates without jeopardising their long-term outcome even for nonresponding patients who received standard
regimen.
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Neuroblastoma (NB) is the most common solid tumour
of early childhood and accounts for the main cause of cancer in
infants (Bernstein et al, 1992). Indeed, nearly one-third of
NBs are diagnosed in children younger than 1 year. Half
of the patients present with localised disease (Hartmann et al,
1983; Rosen et al, 1984) and gross surgical excision is considered
as the main requirement for cure (Evans et al, 1976; Le Tourneau
et al, 1985). Primary surgery can be performed in about
50% of these children and reported survival rates are high
(De Bernardi et al, 1995). Conversely, unresectable tumours
usually have a poorer outcome, unless secondary radical excision
can be performed (Haase et al, 1989, Tsuchida et al, 1989).
Consequently, the efficacy of primary chemotherapy in
allowing subsequent resection is of outstanding importance
(Garaventa et al, 1993; West et al, 1993). Recently, we
reported improved outcome in such patients after primary
chemotherapy including carboplatin and etoposide with
a 90% survival rates and children with unresectable NB and no
N-myc amplification fared as well as those undergoing
primary surgery (Rubie et al, 1998). Moreover, such a strategy
resulted in survival rates over 95% in infants (Rubie et al,
2001). However, immediate haematological toxicity and
transfusion-related risks and possible long-term side effects of
such treatment administered in young children may limit
its use, although preliminary results of their follow-up showed
neither renal nor audition deterioration (Bergeron et al, 2000).
Furthermore, this regimen included anthracyclines and
we are concerned about the possible long-term consequences on
cardiac function. Those considerations prompted us to
evaluate the efficacy of a presumably less toxic chemotherapy
with low-dose cyclophosphamide and vincristine (CV)
in order to attempt a safe surgical excision and ultimately
decrease the risks of long-term sequelae (NBL 94 study). Received 12 December 2002; revised 8 July 2003; accepted 15 July 2003
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lPATIENTS AND METHODS
Patient population
All consecutive and untreated children younger than 12 months at
diagnosis, and referred to SFOP institutions, were eligible in the
study. Evaluation at diagnosis included CT scan or MRI. MIBG and
extensive bone marrow staging (at least two evaluable aspirates
and two trephine biopsies if possible). Tumour volume was
calculated with the product of the theee largest diameters (height,
width and thickness). Urinary catecholamines, serum NSE, ferritin
and LDH were also measured. Histology of the primary (with
either surgical biopsy or tru-cut biopsy) was mandatory to allow
both NB diagnosis according to INSS recommendations (Brodeur
et al, 1993) and MYCN analysis. Only patients with localised NB
and no N-myc amplification (less than 10 copies per haploid
genome) were eligible in the study.
Surgery
Participating institutions were provided with guidelines for
surgical procedures. Resectability was defined according to
imaging data. Procedures that would have resulted in the removal
of major organs were not recommended unless primary che-
motherapy had been administered before any attempt of excision.
Tumours defined as unresectable were lesions that crossed and
infiltrated the mid-line structures, usually encasing large vessels,
and tumours that because of size structure or location, were
deemed as difficult to resect without a high risk of rupture of the
tumour or of major surgical complications. All children presenting
with life-threatening symptoms (cardiac failure, acute respiratory
distress, etc) or dumb-bell tumours and neurological symptoms
were urgently assigned to more intensive chemotherapy using a
combination of carboplatin and etoposide. The appropriateness of
treatment allocation was systematically reviewed. Postoperative
imaging (CT scan or MRI) was required in all patients 1 month
after resection. MIBG scan was recommended in case of
macroscopic residue. Postsurgical staging was defined on the
basis of surgical, pathological reports and postoperative imaging
data.
Chemotherapy
First-line chemotherapy consisted of two courses of low-dose
cyclophosphamide (5mgkg
 1 for days 1–5) and vincristine
(0.05mgkg
 1 on day 1) (CV) given at a 2-week interval
(Figure 1). Following a first evaluation after those two courses,
two more CV courses were to be administered if tumour shrinkage
was over 25% and if the tumour was still unresectable.
Resectability was then assessed and surgery was attempted in the
absence of risk. In case of either no tumour response after the two
first courses of CV, or persisting preoperative risk after four
courses, or life-threatening symptoms, or symptomatic dumb-bell
at diagnosis, a combination of carboplatin (6.6mgkg
 1 on days 1–
3) and etoposide (5mgkg
 1 on days 1–3) (CE) was given, followed
if necessary by two courses of vincristine (0.05mgkg
 1 days 1 and
5), cyclophosphamide (10mgkg
 1 on days 1–5) and doxorubicin
(1mgkg
 1 on days 4 and 5) (CAdO) as previously described
(Rubie et al, 1998). Drug doses were always reduced by 30% in
babies under 1 month of age. No postoperative treatment was
recommended whatever the quality of surgical excision.
Evaluation of response to therapy
Response to therapy was assessed according to INRC criteria
(Brodeur et al, 1993). The value of tumour response, based on
reduction of volume that was considered more significant than
that of urinary catecholamine excretion, was evaluated during
induction therapy (every two courses) before and 1 month after
surgery, and then at least every 3 months. As those children were
young, response was considered as significant if the tumour
shrinkage was over 25% of the volume at diagnosis (objective
response–OR) instead of the usual shrinkage of 50% (partial
response–PR). Indeed, such an objective effect was considered as
encouraging to continue the treatment.
Stastistical analysis
To prevent selection bias, all consecutive patients with newly
diagnosed localised NB in the participating centres were included
in the analysis, whatever the treatment actually administered. The
probabilities of survival were calculated from the time of diagnosis
to death or last follow-up according to the Kaplan–Meier product-
limit method (Fleiss, 1981). In the event-free survival (EFS),
disease progression or relapse and death, whatever the reasons,
were considered as events. Comparisons between mean doses of
chemotherapy and proportions were performed with Student’s t-
and w
2-tests corrected for heterogeneity or Fisher’s exact test,
respectively (Peto et al, 1977). The analysis of EFS times was
performed by Cox’s proportional hazards models and differences
between curves were tested for statistical difference by the log-rank
test (Cox, 1977). The multivariate model was not used as no
prognostic factor was found. All tests were two-tailed.
RESULTS
From January 1995 to December 1999, a total of 301 consecutive
children with confirmed localised NB were registered in the study.
Among them, 134 were infants of whom 82 underwent primary
surgical excision. Among the 52 remaining infants presenting with
and unresectable primary, N-myc was not evaluable in 13 and not
amplified in the other 39. Therefore, the present analysis (NBL 94
study) deals with 39 infants with localised unresectable tumour
Days*     1  2  3        4         5 
Days**     1  2  3       
CAdO 
Days**     1  2  3        4         5 
Low-dose cyclophosphamide–vincristine 
Vincristine (0.05 mg kg−1) 
Cyclophosphamide (5 mg kg−1) 
Carboplatin–Etoposide 
Carboplatin (6.6 mg kg−1) 
Etoposide (5 mg kg−1) 
Doxorubicin (1 mg kg−1) 
Vincristine (0.05 mg kg−1) 
Cyclophosphamide (10 mg kg−1) 
Each course was to be administered every 14 days (*) or every 21 days (**)  
or as soon as haematological criteria were met (WBC > 109 l−1, PMN > 0.5 x 109 l−1, 
Platelets > 100 x 109 l−1). 
Figure 1 Chemotherapy regimen.
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land no N-myc amplification, and reports their outcome as of
October 2002, 33 months after the last patient’s inclusion.
PATIENT CHARACTERISTICS (TABLE 1)
Most primary tumours were abdominal (64%), INSS stage 3 (97%)
and neuroblastoma (97%). As compared to the previous cohort
(NBL 90 study), patient characteristics were similar regarding age,
gender, location of the primary, stage, histology and N-myc status
(Table 1). The only difference was patient’s eligibility. Actually, as
compared to the NBL 94 study, histology was not mandatory at
diagnosis in the NBL 90 study, explaining that more children could
be included in the former one.
Primary chemotherapy (Table 2)
A total of 29 children were to be given low doses of CV according
to the protocol. Among them, one patient presented with an
antenatal diagnosis and spontaneous regression of the tumour was
observed and neither chemotherapy nor surgery was realised.
Thus, 28 received two courses of CV: OR was observed in 14, which
led to two additional courses to 11 of them before surgery. The
remaining three children presenting with a moderately sympto-
matic dumb-bell tumour at diagnosis had no significant improve-
ment or response of the intraspinal component after the two first
CV courses and received subsequently the CE regimen. Four
additional patients were not evaluated correctly after the two CV
courses, three of whom were given two additional courses. No
significant response was observed in 10 and all received CE
according to the protocol. Among the 10 remaining children, six
were given CE as first-line chemotherapy either because of
symptomatic dumb-bell tumour (n¼4) or life-threatening symp-
toms (n¼2), according to the protocol and four for unknown
reason. No relationship could be established between children
having threatening symptoms and tumours with other risk factors
(i.e. size, LDH, etc). Symptomatic dumb-bell NB was observed in
eight children with moderate to severe neurological impairment.
Among them, seven received CE according to the protocol, either
at diagnosis (n¼4) or after CV courses because of persisting
symptoms or no significant response of the intraspinal component
(n¼3). According to the protocol recommendations, neurosurgi-
cal procedure was considered as useless (due to the duration of
deficit) or could be avoided in all but one and neurological
recovery was observed in five of them. As a whole, the observed
response rate (RR) according to first-line chemotherapy was 61%
(n¼20 out of 33 evaluable) and 58% in patients receiving only CV
(n¼14 out of 24). Furthermore, RR to first- and second-line
chemotherapy planned by the protocol was 82% (31 out of 38). No
significant toxicity, particularly haematological, was observed after
CV and the time elapsing between two courses was always less than
2 weeks. The toxicity of CE7CAdO was mainly haematological
and easily manageable as already reported (Rubie et al, 1998,
2001). In summary, 14 children received only CV (four courses), 11
were given CV and CE (two courses each), five had CV–CE and
CAdO (courses each) and eight received CE and CAdo (two
courses each). The cumulative doses of potentially harmful drugs
(i.e. doxorubicin–etoposide and carboplatin) was significantly
lower in the present protocol than that of the previous regimen
given in the NBL 90 study particularly for doxorubicin (2.31 vs
4.29mgkg
 1, Po0.0005) and carboplatin (31.98 vs 41.3mgkg
 1,
Po0.05).
Surgery
Surgical excision was attempted in all children but one (sponta-
neous regression of the tumour with continuous complete
Table 1 Patient characteristics in comparison with the previous cohort
(Rubie et al, 2001)
NBL 90 study NBL 94 study
Number % Number % P
Registered 338 385
Eligible 316/338 93.5 301/385 78.2 o0.001
Infants 152/316 48.1 134/301 44.5 NS
Unresectable 52/152 34.2 52/134 38.8 NS
Evaluable N-myc 37/52 71.2 39/52 75.0 NS
No N-myc amplification 35/37 94.6 39/39 100 NS
Median age
(months, range)
5.4 (1–11) 5.3 (0–11) NS
Dumb-bell tumour 14 40 15 38 NS
NS¼not significant
Table 2 Response to primary chemotherapy and outcome for all patients (n¼39)
First-line chemotherapy Response Second-line chemotherapy Overall response Postoperative status Relapse Outcome
CV, n¼28 14 OR CV, n¼11 None 11 PR 7 CR, 4 VGPR 11 CR
CE, n¼3
a None, n¼2 2 PR 2 VGPR 2 local 2 CR
CAdO, n¼1 1 PR 1 VGPR 1 VGPR
10 NR CE, n¼10 None, n¼6 3 PR 2 CR, 1 VGPR 3 CR
3 NR 2 CR, 1 VGPR 1 local 3 CR
CAdO, n¼4 2 PR 1 CR, 1 PR 2 CR
2N R 2C R 1V G P R ,1P R
4N E C V ,n¼3 None 2 PR, 1 NR 3 CR 3 CR
CE, n¼1 None 1 PR 1 CR 1 CR
CE, n¼10 6 OR CAdO, n¼4 4 PR 1 CR, 3 VGPR 4 VGPR
CV, n¼2 2 PR 1 CR, 1 VGPR 2 CR
3 NR CAdO, n¼2 None 1 PR 1 CR 1 CR
1 NR 1 VGPR 1 local 1 VGPR
CE, n¼1 CAdO, n¼1 1 PR 1 CR 1 VGPR
1 NE CAdO, n¼1 1 PR 1 CR 1 CR
Observation, n¼1 1C R
CV¼cyclophosphamide–vincristine; CE¼carboplatin–etoposide; CAdo¼cyclophosphamide–doxorubicin–vincristine; CR¼complete remission; VGPR¼very good partial
remission; PR¼partial remission; OR¼objective response; NR¼no response.
aThose three children received CE because persisting neurological symptoms or no intraspinal
component shrinkage after CV courses (see text).
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lremission 35 months after diagnosis). Among the 38 remaining
patients, the result of the procedure was complete resection (CR)
in 23, either with a microscopic residue (n¼18) or without (n¼5),
very good partial remission (VGPR) in 14 and partial remission
(simple biopsy) in one. Among children receiving CV only, the
results of the procedure was CR in 10 and VGPR in four. There was
no severe complication related to surgery. Postoperative treatment
was given to three children having residual disease despite
protocol recommendations.
Outcome
As shown in Figure 2, the overall survival (OS) and EFS were 100
and 9075% respectively, with a median follow-up of 55 months
(33–93). No treatment-related death was observed. Relapse
occurred in four children, all local at a median time of 14 months
after diagnosis (12–21 months). Salvage therapy included
conventional doses of chemotherapy (CE, CAdO, etoposide–
cisplatin) followed by surgical excision leading to second CR
(n¼3) or PR (n¼1) with a median follow-up of 24 months after
relapse (15–36).
Survival and prognostic factors
OS is 100%, and as shown in Figure 2, the EFS rates were similar to
those observed in the previous NBL 90 study (90 vs 94%, log
rank¼0.49). No prognostic factor could be identified in that
selected population because of the small size of the cohort and the
very low number of events.
DISCUSSION
The outcome of children with localised NB is favourable,
particularly in those with resectable tumours (Evans et al, 1976;
De Bernardi et al, 1995). Conversely, unresectable NB often carries
a poor prognosis as achieving EFS greater than 50% has proven
difficult (Garaventa et al, 1993, West et al, 1993). In that subset of
patients, surgical excision is recognised as being a major step for
cure (Le Tourneau et al, 1985; Haase et al, 1989; Tsuchida et al,
1989). Consequently, primary chemotherapy allowing resection is
of outstanding importance. The outcome of infants with localised
but unresectable tumours is rarely reported and represents a
challenging issue to limit the risk of immediate morbidity and
treatment-related sequelae. Indeed, the poor prognosis usually
associated with unresectable primaries should be balanced with the
favourable outcome reported in infants (Evans et al, 1976;
Hartmann et al, 1983).
We reported recently in the NBL 90 study a survival rate over
95% in infants presenting with localised and unresectable NB and
with no N-myc amplification, but chemotherapy was intensive
(Rubie et al, 2001). These excellent results may have been due first
to a strict selection of patients having a favourable type of NB (i.e.
extensive staging including MIBG to eliminate metastatic disease).
Second, it has been demonstrated that N-myc amplification had a
major prognostic value in localised NB, including in infants;
indeed, although rare in that subset of patients, N-myc amplifica-
tion has a strong negative influence on outcome (Rubie et al,
1997). Last, primary chemotherapy using a combination of two
courses of CE followed by two courses of CAdO proved to be very
efficient as all infants could undergo safe and satisfying surgical
excision as shown in our previous NBL 90 study. However,
haematological toxicity was significant, although always manage-
able, carrying transfusion-related risks. Moreover, although
subsequent follow-up showed neither auditive nor renal toxicity
(Bergeron et al, 2000), the risk of long-term sequelae due to that
chemotherapy administered in young children cannot be definitely
ruled out. This is the reason why the efficacy of a low-dose CV
regimen as a first-line therapy was investigated in that subset of
patients, providing no urgent situation (i.e. life-threatening sign or
symptomatic dumb-bell tumour) as that regimen is thought to
have a lower or delayed efficacy as compared to CE combination.
The stratification of treatment could not be performed on other
risk factors such as tumour size or location or LDH, since small
primaries may cause threatening symptoms. Thus, treatment
allocation was based on clinical tolerance of the tumour. Indeed,
20% of patients presented with a symptomatic dumb-bell tumour.
In such a situation, any treatment has to be delivered in emergency
to avoid neurologic sequelae and we already reported the efficacy
of that chemotherapy as an alternative to decompressive
laminectomy in order to prevent orthopaedic sequelae as well
(Plantaz et al, 1996). This strategy also seems appropriate for
children presenting with slight neurological symptoms. Indeed, in
this study three of four children were given CE as second-line
chemotherapy, suggesting that CV is not to be recommended in
that situation. Although the number of patients is small, we
confirm the relevance of such an approach in this series. As far as
other patients are concerned, this strategy proved to be efficient as
a safe resection could be attempted in nearly 50% of them after two
to four courses of CV, resulting in a continuous remission. Last,
EFS of the present cohort is 90%, which is similar to that of the
previous series treated with a more intensive primary chemother-
apy (Rubie et al, 2001).
Thus, it appears that we could obtain the same results while
sparing intensive chemotherapy in 50% of these children. Is it
possible to go further in the de-escalation process? The usefulness
of neoadjuvant treatment may be questioned in such a subgroup of
patients. A recent report suggests that apart from surgical excision
adjuvant treatment is not necessary, providing no N-myc
amplification has been found (Kushner et al, 1996). However, this
is a single-centre study that included only four patients with true
INSS stage 3 disease and no dumb-bell tumour, and such results
may be difficult to achieve in a multicentre setting. Furthermore,
surgery may be also harmful, especially in multicentric studies. We
already reported a 3% death rate after postoperative complications
among 186 patients who underwent primary surgical excision
(Rubie et al, 1997). As spontaneous regression of the disease may
be observed in very young children, some investigators are
evaluating the feasibility of observation only in infants presenting
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Figure 2 Event-free survival according to the treatment.
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lwith localised but unresectable NB. Recently, the German group
reported spontaneous regression of the primary after biopsy or
partial resection in infants with unresectable NB, but the cohort
was small and the follow-up still too short to draw any definitive
conclusions (Hero et al, 2002). Those studies are still underway
and their results, providing they are confirmed, may be considered
to establish future strategies in multicentric prospective studies.
In conclusion, low-dose chemotherapy is efficient in about half
of infants presenting with unresectable NB and no N-myc
amplification, allowing safe surgical resection and preventing
long-term late side effects. Those patients have to be strictly
selected (absence of threatening symptom) and followed cautiously
in order to benefit from such a de-escalation strategy without
jeopardising the excellent outcome. This approach is presently
awaiting confirmation in a larger European study.
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